TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/28/2024
Back to search
Official data from USPTO
CRINETICS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
48
Latest update
02/28/2024
Trademark type
Combined
Nice classes
42
Filing date
04/12/2018
Registration date
12/28/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/28/2021
Last transaction
02/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/12/2021
First use in commerce
05/12/2021
Drawing code
3
Owner type
03
Owner location
San Diego, CA
Examiner
KEELEY, ALISON
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "CRINETICS" above the word "PHARMACEUTICALS" with a dot and line spirograph design in the shape of a half circle starting above the letter "I" in "CRINETICS" and wrapping around the first letter "C" in "CRINETICS".
Holders and representatives
Holders
Crinetics Pharmaceuticals, Inc.
Representatives
Danny M. Awdeh Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; medical research for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific researchconducting clinical trials for others
Publications
History of USPTO decisions and trademark events.
48 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/28/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/28/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/28/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/28/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/28/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/20/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/19/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/02/2021
IUAF
USE AMENDMENT FILED
10/29/2021
EISU
TEAS STATEMENT OF USE RECEIVED
10/29/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/08/2021
EX5G
SOU EXTENSION 5 GRANTED
05/07/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/07/2021
EXT5
SOU EXTENSION 5 FILED
04/29/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/29/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/30/2020
EX4G
SOU EXTENSION 4 GRANTED
10/28/2020
EXT4
SOU EXTENSION 4 FILED
10/28/2020
EEXT
SOU TEAS EXTENSION RECEIVED
10/28/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/28/2020
EX3G
SOU EXTENSION 3 GRANTED
04/24/2020
EXT3
SOU EXTENSION 3 FILED
04/24/2020
EEXT
SOU TEAS EXTENSION RECEIVED
04/24/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/23/2019
EX2G
SOU EXTENSION 2 GRANTED
10/21/2019
EXT2
SOU EXTENSION 2 FILED
10/21/2019
EEXT
SOU TEAS EXTENSION RECEIVED
10/21/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/19/2019
EX1G
SOU EXTENSION 1 GRANTED
04/17/2019
EXT1
SOU EXTENSION 1 FILED
04/17/2019
EEXT
SOU TEAS EXTENSION RECEIVED
04/17/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/17/2019
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/17/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/13/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/18/2018
PUBO
PUBLISHED FOR OPPOSITION
09/18/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/29/2018
ALIE
ASSIGNED TO LIE
08/16/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
08/06/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/06/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
08/06/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/06/2018
DOCK
ASSIGNED TO EXAMINER
07/31/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/24/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/21/2018
NWAP
NEW APPLICATION ENTERED
04/16/2018
Continuous trademark protection
Get notified about every new filing that threatens CRINETICS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.